Inactivation of TGF-β signaling in CAR-T cells.
作者信息
Yang Zaopeng, Fu Yang-Xin
机构信息
Changping Laboratory, Beijing, 102206, China.
Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
出版信息
Cell Mol Immunol. 2024 Mar;21(3):309-310. doi: 10.1038/s41423-023-01123-9. Epub 2024 Feb 26.
Abstract
摘要
相似文献
1
Inactivation of TGF-β signaling in CAR-T cells.嵌合抗原受体T细胞（CAR-T细胞）中转化生长因子-β（TGF-β）信号通路的失活
Cell Mol Immunol. 2024 Mar;21(3):309-310. doi: 10.1038/s41423-023-01123-9. Epub 2024 Feb 26.
2
Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal.通过逆转转化生长因子-β信号增强免疫抑制性肿瘤微环境中的嵌合抗原受体T细胞功能。
Mol Ther. 2025 Feb 5;33(2):688-702. doi: 10.1016/j.ymthe.2024.12.014. Epub 2024 Dec 13.
3
β-.β-。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000676.
4
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.在基因工程肿瘤抗原反应性 T 细胞中抑制 TGF-β 信号显著增强肿瘤治疗效果。
Gene Ther. 2013 May;20(5):575-80. doi: 10.1038/gt.2012.75. Epub 2012 Sep 13.
5
IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.IL-13Rα2/TGF-β 双特异性 CAR-T 细胞可克服 TGF-β 介导的免疫抑制，增强胶质母细胞瘤的抗肿瘤反应。
Neuro Oncol. 2024 Oct 3;26(10):1850-1866. doi: 10.1093/neuonc/noae126.
6
CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.CD28-ζ CAR T 细胞通过 IL-2 信号抵抗 TGF-β 的抑制作用，而这种作用可以通过工程化的 IL-7 自分泌环来模拟。
Mol Ther. 2018 Sep 5;26(9):2218-2230. doi: 10.1016/j.ymthe.2018.07.005. Epub 2018 Jul 10.
7
Lipopolysaccharide Induces Resistance to CAR-T Cell Therapy of Colorectal Cancer Cells through TGF-β-Mediated Stemness Enhancement.脂多糖通过转化生长因子-β介导的干性增强诱导大肠癌细胞对CAR-T细胞疗法产生抗性。
Mol Pharm. 2025 Apr 7;22(4):1790-1803. doi: 10.1021/acs.molpharmaceut.4c00264. Epub 2025 Mar 21.
8
Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.转化生长因子-β信号在肿瘤中CD39⁺CD73⁺髓样细胞生成中的作用。
J Immunol. 2014 Sep 15;193(6):3155-64. doi: 10.4049/jimmunol.1400578. Epub 2014 Aug 15.
9
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.显性失活 TGF-β 受体增强 PSMA 靶向的人源 CAR T 细胞增殖并增强前列腺癌清除。
Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.
10
TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.嵌合 TGF-β/IL-7 开关受体表达的 CAR-T 细胞抑制 CD19 阳性 B 细胞淋巴瘤的复发。
Int J Mol Sci. 2021 Aug 13;22(16):8706. doi: 10.3390/ijms22168706.
引用本文的文献
1
Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.结直肠癌中的过继性细胞疗法：嵌合抗原受体T细胞的进展
World J Gastrointest Oncol. 2025 Jul 15;17(7):106723. doi: 10.4251/wjgo.v17.i7.106723.
本文引用的文献
1
SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.CAR-T 细胞中 SMAD7 的表达可提高实体瘤的持久性和安全性。
Cell Mol Immunol. 2024 Mar;21(3):213-226. doi: 10.1038/s41423-023-01120-y. Epub 2024 Jan 4.
2
Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer.SMAD7 的过表达可改善针对非小细胞肺癌的 EGFR 靶向人 CAR-T 细胞的功能。
Respirology. 2023 Sep;28(9):869-880. doi: 10.1111/resp.14541. Epub 2023 Jun 28.
3
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.PSMA 靶向 TGFβ 不敏感装甲 CAR T 细胞治疗转移性去势抵抗性前列腺癌：一项 1 期试验。
Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21.
4
TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.嵌合 TGF-β/IL-7 开关受体表达的 CAR-T 细胞抑制 CD19 阳性 B 细胞淋巴瘤的复发。
Int J Mol Sci. 2021 Aug 13;22(16):8706. doi: 10.3390/ijms22168706.
5
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.工程化细胞因子信号转导以改善 CAR T 细胞效应功能。
Front Immunol. 2021 Jun 4;12:684642. doi: 10.3389/fimmu.2021.684642. eCollection 2021.
6
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.通过CRISPR抑制转化生长因子-β可提高嵌合抗原受体T细胞对实体瘤的长期疗效。
JCI Insight. 2020 Feb 27;5(4):133977. doi: 10.1172/jci.insight.133977.
7
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.显性失活 TGF-β 受体增强 PSMA 靶向的人源 CAR T 细胞增殖并增强前列腺癌清除。
Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.
8
T Cell Receptor-Regulated TGF-β Type I Receptor Expression Determines T Cell Quiescence and Activation.T 细胞受体调控的 TGF-β Ⅰ型受体表达决定 T 细胞的静止和激活。
Immunity. 2018 Apr 17;48(4):745-759.e6. doi: 10.1016/j.immuni.2018.03.025.
9
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.程序性死亡蛋白1（PD-1）阻断调节嵌合抗原受体（CAR）修饰的T细胞：为CAR补充能量。
Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28.
10
TGF-β activation and function in immunity.转化生长因子-β（TGF-β）在免疫中的激活与功能
Annu Rev Immunol. 2014;32:51-82. doi: 10.1146/annurev-immunol-032713-120257. Epub 2013 Dec 2.
Zotero 插件